Jason Gotlib
Publications
- Accessory splenules in autoimmune hemolytic anemia. Am J Hematol. 2013; (2): 156
- Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2013; (10): 1285-92
- International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. Blood. 2013; (13): 2393-401
- DNA methylation analysis of ALOX12 and GSTM1 in acute myeloid leukaemia identifies prognostically significant groups. Br J Haematol. 2012; (2): 182-90
- ICON: Eosinophil Disorders. World Allergy Organ J. 2012; (12): 174-181
- Mast cells and eosinophils in mastocytosis, chronic eosinophilic leukemia, and non-clonal disorders. Semin Hematol. 2012; (2): 128-37
- Next-generation sequencing in hematologic malignancies: what will be the dividends? Ther Adv Hematol. 2012; (6): 333-9
- Tailored temozolomide therapy according to MGMT methylation status for elderly patients with acute myeloid leukemia. Am J Hematol. 2012; (1): 45-50
- World Health Organization-defined eosinophilic disorders: 2012 update on diagnosis, risk stratification, and management. Am J Hematol. 2012; (9): 903-14
- A novel splice donor mutation in the thrombopoietin gene leads to exon 2 skipping in a Filipino family with hereditary thrombocythemia. Blood. 2011; (26): 6988-90
- Impact of TET2 mutations on mRNA expression and clinical outcomes in MDS patients treated with DNA methyltransferase inhibitors. Hematol Oncol. 2011; (3): 157-60
- Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol. 2011; (7): 789-96
- World Health Organization-defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and management. Am J Hematol. 2011; (8): 677-88
- Design and evaluation of a real-time PCR assay for quantification of JAK2 V617F and wild-type JAK2 transcript levels in the clinical laboratory. J Mol Diagn. 2010; (1): 58-64
- Eosinophilic myeloid disorders: new classification and novel therapeutic strategies. Curr Opin Hematol. 2010; (2): 117-24
- JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms. Expert Rev Hematol. 2010; (3): 323-37
- Myelomastocytic leukemia versus mast cell leukemia versus systemic mastocytosis associated with acute myeloid leukemia: a diagnostic challenge. Am J Hematol. 2010; (8): 600-6
- Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood. 2010; (6): 988-92
- Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: a single-center experience. Am J Hematol. 2010; (11): 877-81
- A Phase II intra-patient dose-escalation trial of weight-based darbepoetin alfa with or without granulocyte-colony stimulating factor in myelodysplastic syndromes. Am J Hematol. 2009; (1): 15-20
- Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system. Blood. 2009; (9): 1906-8
- Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation. Proc Natl Acad Sci U S A. 2009; (10): 3925-9
- Molecular stratification of patients with normal karyotype acute myeloid leukemia based on initial assessment of FLT3-internal tandem duplication status at first complete remission. Leuk Lymphoma. 2009; (5): 851-3
- Monoclonal antibodies against IREM-1: potential for targeted therapy of AML. Leukemia. 2009; (9): 1587-97
- Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens. Nat Med. 2009; (5): 566-71
- On being metachromatic: mystique and misunderstanding in mastocytosis. Am J Hematol. 2009; (12): 779-81
- RNAi screen for rapid therapeutic target identification in leukemia patients. Proc Natl Acad Sci U S A. 2009; (21): 8695-700
- When yellow jackets attack: recurrent and severe anaphylactic reactions to insect bites and stings. Am J Hematol. 2009; (12): 843-6
- Antiangiogenic therapy in myelodysplastic syndromes: is there a role? Curr Hematol Malig Rep. 2008; (1): 10-8
- Chronic eosinophilic leukemia/hypereosinophilic syndrome. Cancer Treat Res. 2008: 69-106
- Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias. Leukemia. 2008; (11): 1999-2010
- Gene expression and pathway analysis of immune thrombocytopenic purpura. Br J Haematol. 2008; (1): 99-103
- Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors. Cancer Cell. 2008; (4): 321-30
- A patient with paroxysmal nocturnal hemoglobinuria, T cell large granular lymphocyte clonal expansion, and monoclonal gammopathy of undetermined significance. Am J Hematol. 2006; (11): 870-4
- Detection of the JAK2 V617F mutation by LightCycler PCR and probe dissociation analysis. J Mol Diagn. 2006; (3): 330-4
- Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapy. Best Pract Res Clin Haematol. 2006; (3): 535-69
- KIT mutations in mastocytosis and their potential as therapeutic targets. Immunol Allergy Clin North Am. 2006; (3): 575-92
- Use of urine flow cytometry to verify relapse of Burkitt's lymphoma in the genitourinary system. J Clin Oncol. 2006; (27): 4515-6
- Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood. 2005; (8): 2865-70
- Farnesyltransferase inhibitor therapy in acute myelogenous leukemia. Curr Hematol Rep. 2005; (1): 77-84
- Molecular classification and pathogenesis of eosinophilic disorders: 2005 update. Acta Haematol. 2005; (1): 7-25
- Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med. 2004; (7): 657-67
- Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate. Semin Cancer Biol. 2004; (4): 307-15
- Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate. Semin Cancer Biol. 2004; (1): 23-31
- The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood. 2004; (8): 2879-91
- Novel biospecific agents for the treatment of myelodysplastic syndromes. J Natl Compr Canc Netw. 2003; (4): 473-80
Help
Trial Administration